Loading...

iBio

AMEX:IBIO
Snowflake Description

Overvalued with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IBIO
AMEX
$16M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The last earnings update was 15 days ago. More info.


Add to Portfolio Compare Print
IBIO Share Price and Events
7 Day Returns
1.1%
AMEX:IBIO
-0.3%
US Biotechs
-2.1%
US Market
1 Year Returns
-47.5%
AMEX:IBIO
-5%
US Biotechs
1.3%
US Market
IBIO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
iBio (IBIO) 1.1% -1.3% -17.4% -47.5% -87.9% -78.3%
US Biotechs -0.3% -2.5% -5.2% -5% 4.2% 10.1%
US Market -2.1% -4.2% 0% 1.3% 33.5% 38%
1 Year Return vs Industry and Market
  • IBIO underperformed the Biotechs industry which returned -5% over the past year.
  • IBIO underperformed the Market in United States of America which returned 1.3% over the past year.
Price Volatility
IBIO
Industry
5yr Volatility vs Market
Related Companies

IBIO Value

 Is iBio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for iBio. This is due to cash flow or dividend data being unavailable. The share price is $0.809.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for iBio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are iBio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AMEX:IBIO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.05
AMEX:IBIO Share Price ** AMEX (2019-05-24) in USD $0.81
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 17.95x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of iBio.

AMEX:IBIO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:IBIO Share Price ÷ EPS (both in USD)

= 0.81 ÷ -1.05

-0.77x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • iBio is loss making, we can't compare its value to the US Biotechs industry average.
  • iBio is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does iBio's expected growth come at a high price?
Raw Data
AMEX:IBIO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.77x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.19x
United States of America Market PEG Ratio Median Figure of 2,120 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for iBio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on iBio's assets?
Raw Data
AMEX:IBIO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.35
AMEX:IBIO Share Price * AMEX (2019-05-24) in USD $0.81
United States of America Biotechs Industry PB Ratio Median Figure of 418 Publicly-Listed Biotechs Companies 3.19x
United States of America Market PB Ratio Median Figure of 5,207 Publicly-Listed Companies 1.8x
AMEX:IBIO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:IBIO Share Price ÷ Book Value per Share (both in USD)

= 0.81 ÷ 0.35

2.3x

* Primary Listing of iBio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • iBio is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess iBio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. iBio has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IBIO Future Performance

 How is iBio expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iBio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.4%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is iBio expected to grow at an attractive rate?
  • Unable to compare iBio's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare iBio's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare iBio's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
AMEX:IBIO Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.4%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AMEX:IBIO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AMEX:IBIO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 1 -13 -18
2018-12-31 1 -12 -18
2018-09-30 0 -11 -17
2018-06-30 0 -13 -16
2018-03-31 1 -14 -16
2017-12-31 0 -14 -16
2017-09-30 0 -14 -15
2017-06-30 0 -13 -15
2017-03-31 1 -12 -13
2016-12-31 1 -11 -12
2016-09-30 1 -9 -11
2016-06-30 1 -8 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if iBio is high growth as no earnings estimate data is available.
  • Unable to determine if iBio is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AMEX:IBIO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from iBio Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:IBIO Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.05
2018-12-31 -1.17
2018-09-30 -1.32
2018-06-30 -1.54
2018-03-31 -1.64
2017-12-31 -1.75
2017-09-30 -1.72
2017-06-30 -1.64
2017-03-31 -1.45
2016-12-31 -1.38
2016-09-30 -1.31
2016-06-30 -1.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if iBio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of IBIO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. iBio's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. iBio's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess iBio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
iBio has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IBIO Past Performance

  How has iBio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare iBio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • iBio does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare iBio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare iBio's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
iBio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from iBio Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:IBIO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 1.31 -17.77 12.10 4.89
2018-12-31 0.87 -17.51 11.86 4.41
2018-09-30 0.37 -16.94 11.06 4.13
2018-06-30 0.44 -16.37 10.69 3.99
2018-03-31 0.50 -16.28 10.58 4.06
2017-12-31 0.46 -16.19 10.82 4.23
2017-09-30 0.38 -15.45 10.58 4.28
2017-06-30 0.39 -14.62 10.55 4.12
2017-03-31 0.52 -12.91 9.83 3.86
2016-12-31 0.86 -12.00 9.40 3.77
2016-09-30 0.92 -11.02 8.73 3.43
2016-06-30 0.95 -9.76 7.69 3.16
2016-03-31 0.99 -8.97 6.96 3.07
2015-12-31 0.96 -7.61 5.78 2.83
2015-09-30 1.19 -7.02 5.39 2.86
2015-06-30 1.85 -6.63 5.02 3.50
2015-03-31 1.74 -5.88 4.51 3.15
2014-12-31 1.39 -5.48 4.24 2.68
2014-09-30 1.02 -5.46 3.99 2.53
2014-06-30 0.21 -3.67 3.89 1.90
2014-03-31 0.62 -3.84 3.90 2.45
2013-12-31 0.62 -4.32 4.18 2.74
2013-09-30 0.62 -3.77 4.17 2.81
2013-06-30 1.01 -6.20 4.24 3.43
2013-03-31 0.74 -6.24 4.65 3.52
2012-12-31 1.11 -7.58 4.66 4.20
2012-09-30 1.35 -8.11 5.37 4.70
2012-06-30 1.28 -5.68 5.54 4.98

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if iBio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if iBio has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if iBio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess iBio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
iBio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IBIO Health

 How is iBio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up iBio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • iBio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • iBio's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of iBio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from iBio Company Filings, last reported 1 month ago.

AMEX:IBIO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 6.90 24.94 9.04
2018-12-31 11.08 24.99 13.36
2018-09-30 13.03 25.03 16.01
2018-06-30 16.16 25.08 15.93
2018-03-31 4.15 25.13 3.40
2017-12-31 7.81 25.18 7.31
2017-09-30 6.29 25.22 5.92
2017-06-30 8.92 25.27 8.09
2017-03-31 12.95 25.31 12.42
2016-12-31 17.15 25.35 16.33
2016-09-30 20.70 25.39 20.10
2016-06-30 24.04 25.44 23.01
2016-03-31 22.92 25.48 21.89
2015-12-31 7.88 0.00 6.73
2015-09-30 9.81 0.00 8.38
2015-06-30 11.23 0.00 9.49
2015-03-31 10.19 0.33 8.08
2014-12-31 9.57 0.34 7.36
2014-09-30 5.44 0.56 3.49
2014-06-30 6.10 0.00 3.59
2014-03-31 7.00 0.00 4.33
2013-12-31 7.95 0.00 5.68
2013-09-30 5.68 0.10 3.44
2013-06-30 5.07 1.70 4.41
2013-03-31 2.30 0.00 1.53
2012-12-31 3.72 0.00 2.82
2012-09-30 4.57 0.00 4.28
2012-06-30 6.17 0.00 5.62
  • iBio's level of debt (361.3%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 361.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • iBio has less than a year of cash runway based on current free cash flow.
  • iBio has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.6% each year.
X
Financial health checks
We assess iBio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. iBio has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IBIO Dividends

 What is iBio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from iBio dividends.
If you bought $2,000 of iBio shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate iBio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate iBio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AMEX:IBIO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as iBio has not reported any payouts.
  • Unable to verify if iBio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of iBio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as iBio has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess iBio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can iBio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. iBio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IBIO Management

 What is the CEO of iBio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Robert Kay
COMPENSATION $314,899
AGE 78
TENURE AS CEO 10.8 years
CEO Bio

Mr. Robert B. Kay serves as Managing Director of Integrated BioPharma, Inc. He serves as a Principal, Co-Owner and Chairman of Seaway Biltmore, Inc., a hotel ownership and management company. Mr. Kay serves as Executive Chairman and Chief Executive Officer of iBio, Inc. (formerly iBioPharma Inc) since August 2008. He has more than 35 years of experience in the legal, business and pharmaceutical fields. He served as the Chairman of Paxis Pharmaceuticals, Inc. since 2002 and served as its Chief Executive Officer and President. His legal career has included considerable activity in the area of Corporate and Finance Law with broad experience in counseling financial institutions such as banks and credit card companies and in structuring and accomplishing major acquisitions and disposition transactions of banks and financial institutions domestically and internationally. He started his practice of corporate law in New York City in 1966. From 1983 to 2003 he was a Founder and Senior Corporate Partner of the New York City law firm Kay Collyer & Boose LLP where he oversaw a broad-based general corporate practice which included international transactional representation of both domestic and foreign clients, mergers and acquisitions, securities, franchising/licensing, partnerships/joint ventures, software, e-commerce and other financial transactions, with particular emphasis in the banking, credit card and hotel/hospitality industries. He has served also as a Senior Advisor to multi-national corporations in the banking, credit card and financial services industries. From January 1998 to August 2001, Mr. Kay served as a General Counsel of NIA Group, LLC. From August 2001 he has served as the President of Links Insurance Services LLC. He has been a Director of iBio, Inc since August 2008. He served as a Director of Integrated Biopharma Inc. since November 2003 to November 2008. He served as a Director of Taxolog, Inc. Mr. Canarick is a Certified Public Accountant and Attorney. Mr. Kay is a graduate of Cornell University's College of Arts and Sciences where he earned a Bachelor of Arts in Economics in 1963 and of New York University Law School where he earned a Juris Doctor degree in 1966.

CEO Compensation
  • Robert's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Robert's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the iBio management team in years:

6.3
Average Tenure
64
Average Age
  • The average tenure for the iBio management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Robert Kay

TITLE
Executive Chairman & CEO
COMPENSATION
$315K
AGE
78
TENURE
10.8 yrs

Robert Erwin

TITLE
President
COMPENSATION
$252K
AGE
65
TENURE
10.8 yrs

James Mullaney

TITLE
Chief Financial Officer
COMPENSATION
$240K
AGE
47
TENURE
2.2 yrs

Terry Ryan

TITLE
Chief Scientific Officer
COMPENSATION
$200K
AGE
63
TENURE
7.2 yrs

Renato Lobo

TITLE
Chief Medical Officer

R. Holtz

TITLE
President of iBio CDMO
TENURE
0.3 yrs

Carlos Picosse

TITLE
Chief Executive Officer of IBio Brazil
TENURE
5.5 yrs

Betsy Moyle

TITLE
Secretary
Board of Directors Tenure

Average tenure and age of the iBio board of directors in years:

10
Average Tenure
75
Average Age
  • The tenure for the iBio board of directors is about average.
Board of Directors

Robert Kay

TITLE
Executive Chairman & CEO
COMPENSATION
$315K
AGE
78
TENURE
10.8 yrs

James Hill

TITLE
Independent Director
COMPENSATION
$40K
AGE
72
TENURE
10.8 yrs

Glenn Chang

TITLE
Independent Director
COMPENSATION
$15K
AGE
70
TENURE
10.8 yrs

Vidadi Yusibov

TITLE
Member of Scientific Advisory Board
AGE
57
TENURE
14.7 yrs

Philip Russell

TITLE
Independent Director
COMPENSATION
$15K
AGE
86
TENURE
9.2 yrs

John McKey

TITLE
Independent Director
COMPENSATION
$15K
AGE
75
TENURE
10.8 yrs

Seymour Flug

TITLE
Independent Director
COMPENSATION
$15K
AGE
83
TENURE
6.4 yrs

Timothy Blackwell

TITLE
Member of Clinical Advisory Board
TENURE
4.8 yrs

Richard Silver

TITLE
Member of Clinical Advisory Board
TENURE
4.8 yrs

J. Huggins

TITLE
Member of Clinical Advisory Board
TENURE
4.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
13. Jul 18 Buy Eastern Capital Limited Company 12. Jul 18 12. Jul 18 2,200,000 $0.90 $1,980,000
28. Jun 18 Buy Eastern Capital Limited Company 26. Jun 18 26. Jun 18 1,683,334 $0.90 $1,515,001
X
Management checks
We assess iBio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. iBio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IBIO News

Simply Wall St News

Is iBio, Inc. (NYSEMKT:IBIO) A Volatile Stock?

(NYSEMKT:IBIO), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … Check out our latest analysis for iBio What IBIO's beta value tells investors With a beta of 1.01, (which is quite close to 1) the share price of iBio has historically been about as voltile as the broader market.

Simply Wall St -

Investors Who Bought iBio (NYSEMKT:IBIO) Shares Three Years Ago Are Now Down 87%

So take a moment to sympathize with the long term shareholders of iBio, Inc. … It seems likely some shareholders believe that iBio has the funding to invent a new product before too long. … But with the share price diving 49% per year, over 3 years, it's probably fair to say that some shareholders no longer believe the company will succeed.

Simply Wall St -

Here's What We Think About iBio, Inc.'s (NYSEMKT:IBIO) CEO Pay

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Robert Kay's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below US$200m

Simply Wall St -

Can We See Significant Institutional Ownership On The iBio, Inc. (NYSEMKT:IBIO) Share Register?

A look at the shareholders of iBio, Inc. … Generally speaking, as a company grows, institutions will increase their ownership. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Who Really Owns iBio Inc (NYSEMKT:IBIO)?

I am going to take a deep dive into iBio Inc’s (NYSEMKT:IBIO) most recent ownership structure, not a frequent subject of discussion among individual investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … While these are more of a long-term investor’s concern, short-term investors may find the impact of institutional trading overwhelming enough to lose out on what could be a potential opportunity.

Simply Wall St -

Does iBio Inc (NYSEMKT:IBIO) Go Up With The Market?

Check out our latest analysis for iBio What is IBIO’s market risk? … Based on this beta value, IBIO appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … Depending on the composition of your portfolio, low-beta stocks such as IBIO is valuable to lower your risk of market exposure, in particular, during times of economic decline.

Simply Wall St -

Should You Be Concerned About iBio Inc's (NYSEMKT:IBIO) Shareholders?

Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … In essence, insider ownership is more about the alignment of shareholders' interests with the management. … However, an ownership of this size may be relatively insignificant, meaning that these shareholders may not have the potential to influence IBIO's business strategy.

Simply Wall St -

iBio Inc (NYSEMKT:IBIO): Does The Earnings Decline Make It An Underperformer?

Today I will examine iBio Inc's (AMEX:IBIO) latest earnings update (31 December 2017) and compare these figures against its performance over the past couple of years, in addition to how the rest of IBIO's industry performed. … View our latest analysis for iBio Was IBIO's recent earnings decline worse than the long-term trend and the industry? … I like to use data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data.

Simply Wall St -

Does iBio Inc's (NYSEMKT:IBIO) CEO Salary Reflect Performance?

Therefore I will use earnings as a proxy of Kay's performance in the past year. … Over the last year IBIO released negative earnings of -US$16.19M , which is a further decline from prior year's loss of -US$12.00M. … Normally I would look at market cap and earnings as a proxy for performance, however, IBIO's negative earnings lower the effectiveness of this method.

Simply Wall St -

Should You Be Concerned About iBio Inc's (NYSEMKT:IBIO) -31.1% Earnings Decline?

Below, I will run you through a simple sense check to build perspective on how iBio is doing by comparing its most recent earnings with its historical trend, in addition to the performance of its biotechnology industry peers. … See our latest analysis for iBio Commentary On IBIO's Past Performance I look at data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … Viewing growth from a sector-level, the US biotechnology industry has been growing its average earnings by double-digit 11.07% in the past twelve months, and 20.18% over the previous few years.

Simply Wall St -

IBIO Company Info

Description

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company’s services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.

Details
Name: iBio, Inc.
IBIO
Exchange: AMEX
Founded:
$15,939,288
19,702,458
Website: http://www.ibioinc.com
Address: iBio, Inc.
600 Madison Avenue,
Suite 1601,
New York,
New York, 10022,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX IBIO Common Stock NYSE MKT LLC US USD 18. Aug 2008
DB 0JVN Common Stock Deutsche Boerse AG DE EUR 18. Aug 2008
Number of employees
Current staff
Staff numbers
54
iBio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/25 00:14
End of day share price update: 2019/05/24 00:00
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.